
Metabolic
Retatrutide 40mg
Triple agonist: GLP-1 / GIP / glucagon
Overview
A synthetic triple incretin receptor agonist, supplied at a 40 mg fill. Supplied lyophilized for in-vitro study of GLP-1, GIP and glucagon receptor signalling.
Receptor pharmacology
Simultaneous agonism at the GLP-1, GIP and glucagon receptors. The added glucagon receptor activity is what separates retatrutide from GLP-1-only and GLP-1 / GIP dual agonists in receptor-binding and signalling assays.
Laboratory handling
Research use disclaimer
Sacred Peptides does not provide dosing recommendations for human use. Retatrutide 40mg is supplied for in-vitro laboratory research only. Any concentration ranges referenced on this page or in cited studies describe the parameters used in that research and are not instructions.
- Not a drug. Not approved by Health Canada or the FDA for human use.
- Not intended to diagnose, treat, cure, or prevent any disease.
- Not for use in humans, pregnant or nursing individuals, or animals outside a controlled research setting.
- Handling, storage, and disposal are the responsibility of a qualified researcher.